Antengene Corporation Limited (HK:6996) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Antengene Corporation Limited has announced the approval of XPOVIO® as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma in China. This marks a significant milestone for the company, enhancing its portfolio in the realm of hematology oncology treatments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.